Workflow
Elanco(ELAN)
icon
Search documents
ELAN SHAREHOLDER NEWS: BFA Law is Investigating Elanco for Securities Fraud – Investors that Suffered Losses are Encouraged to Contact the Firm to Discuss Your Rights (NYSE:ELAN)
Newsfilter· 2024-08-06 11:12
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...
ELAN SHAREHOLDER NEWS: BFA Law is Investigating Elanco for Securities Fraud – Investors that Suffered Losses are Encouraged to Contact the Firm to Discuss Your Rights (NYSE:ELAN)
GlobeNewswire News Room· 2024-08-06 11:12
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...
ELAN Investors Have Opportunity to Join Elanco Animal Health Incorporated Securities Fraud Investigation with the Schall Law Firm
Prnewswire· 2024-08-02 15:15
LOS ANGELES, Aug. 2, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE: ELAN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Elanco touted its Zenrelia and Credelio Quattro treatments for anim ...
Elanco (NYSE:ELAN) Investors are Alerted that the Company is Under Inquiry for Securities Fraud by BFA Law and are Urged to Contact the Firm if You Lost Money
Newsfilter· 2024-08-02 10:27
NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...
ELAN INVESTOR ALERT: Elanco is being Investigated for Securities Fraud by BFA Law; Investors that Suffered Losses are Notified to Contact the Firm (NYSE:ELAN)
GlobeNewswire News Room· 2024-07-31 10:21
Why Did Elanco's Stock Drop? With respect to these treatments, the company stated that the FDA "has all data necessary to complete its review. All technical sections, including the label, are expected to be approved before the end of June [2024]." However, on June 27, 2024, Elanco announced that it expected the FDA would not approve either drug in June 2024 and that Zenrelia would come with a boxed warning on safety. As a result of the news, Elanco's stock price declined over 21%, from $17.97 per share on J ...
Elanco Releases 2023 Environmental, Social and Governance Report, Delivering Healthier Outcomes for Animals, People, Planet and Enterprise
Prnewswire· 2024-07-30 12:27
Additionally, the company has refreshed its Sustainability Accounting Standards Board (SASB) and Taskforce on Climate-related Financial Disclosure (TCFD) reports, as well as its extensive suite of issue briefs covering leading ESG topics and KPIs, to reflect 2023 data. "As we celebrate our 70th anniversary, we're encouraged by the progress our global team has made to continue to raise the bar on our sustainability efforts. Our efforts are embedded across the business to reduce our footprint, increase the ex ...
ELAN FRAUD INVESTIGATION: Elanco (NYSE:ELAN) Shareholders with Losses are Notified that BFA Law is Investigating the Company for Securities Fraud and Should Contact the Firm
GlobeNewswire News Room· 2024-07-29 11:08
NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. Why Did Elanco's Stock Drop? As a result of the news, Elanco's stock price declined over 21%, from $17.97 per share on June 26, 2024 to $14.27 per share on June 27, 2024. BFA Law is investigating whether Elanco and certain of its executives made materially false and/or misleadi ...
ELAN STOCK NOTICE: Elanco (NYSE:ELAN) Shareholders are Informed that the Company is being Investigated for Securities Fraud – Contact BFA Law if you Suffered Losses
GlobeNewswire News Room· 2024-07-27 11:11
What Can You Do? If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Elanco develops products to treat diseases in animals. Two of the most important treatments in the company's development pipeline are currently being reviewed by the U.S. Food and Drug Administration ("FDA"). The treatments are named Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, which is a broad s ...
Elanco (ELAN) Stock Declines After Sale of Aqua Business
ZACKS· 2024-07-22 15:21
Shares of Elanco Animal Health (ELAN) have declined 6.1% since Jul 9, following the completion of the divestiture of its aqua business to Merck Animal Health, a subsidiary of Merck & Co. (MRK) , for approximately $1.3 billion in cash. Although its shares are down, Elanco is focused on the long-term positive strategic move that will enable the company to concentrate on high-value opportunities in pet health and livestock sustainability while enhancing its financial flexibility. The company plans to use the n ...
ELAN ONGOING INVESTIGATION: BFA Law Reminds Elanco (NYSE:ELAN) Stockholders that Incurred Losses on their Investment to Contact Us about Ongoing Securities Fraud Investigation
GlobeNewswire News Room· 2024-07-22 10:24
If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Elanco develops products to treat diseases in animals. Two of the most important treatments in the company's development pipeline are currently being reviewed by the U.S. Food and Drug Administration ("FDA"). The treatments are named Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, which is a broad spectrum oral para ...